ruxolitinib

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Thalassemia Major

Conditions

Thalassemia Major

Trial Timeline

May 28, 2014 → Apr 12, 2016

NCT ID

NCT02049450

About ruxolitinib

ruxolitinib is a phase 2 stage product being developed by Novartis for Thalassemia Major. The current trial status is completed. This product is registered under clinical trial identifier NCT02049450. Target conditions include Thalassemia Major.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (16)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05269771	Pre-clinical	Completed	—	—	Polycythemia Vera
NCT04745637	Pre-clinical	Active	—	—	Primary Myelofibrosis (PMF)
NCT04337359	Pre-clinical	Completed	—	—	Severe/Very Severe COVID-19 Illness
NCT06824103	Approved	Recruiting	Sep 9, 2025	Jan 11, 2032	Graft vs. Host Disease
NCT06462469	Approved	Recruiting	Jul 4, 2024	Feb 17, 2028	Steroid-refractory Acute Graft Versus Host Disease
NCT03491215	Phase 1/2	Completed	Feb 21, 2019	Feb 2, 2023	Acute Graft Versus Host Disease
NCT02966353	Phase 2	Completed	Mar 31, 2017	Feb 15, 2019	Primary Myelofibrosis
NCT02292446	Phase 3	Completed	Nov 21, 2014	Dec 29, 2017	Polycythemia Vera
NCT02091752	Phase 2	Terminated	Sep 1, 2014	Feb 1, 2015	Primary Myelofibrosis
NCT02049450	Phase 2	Completed	May 28, 2014	Apr 12, 2016	Thalassemia Major
NCT02072057	Phase 2	Terminated	Apr 20, 2014	Nov 30, 2018	Cancer Cachexia
NCT02015208	Phase 1/2	Completed	Apr 1, 2014	Jul 1, 2015	Chronic Lymphocytic Leukemia
NCT02087059	Phase 3	Completed	Apr 1, 2014	Apr 1, 2015	Primary Myelofibrosis (MF)
NCT01877005	Phase 2	Completed	Jul 4, 2013	Jun 12, 2018	Hodgkin's Lymphoma
NCT01317875	Phase 1	Completed	Mar 31, 2011	Dec 31, 2019	Myelofibrosis
NCT01392443	Phase 2	Completed	Oct 14, 2010	Oct 31, 2017	Primary Myelofibrosis (MF)

Competing Products

20 competing products in Thalassemia Major

See all competitors

Product	Company	Stage	Hype Score
Luspatercept	Merck	Phase 2	52
luspatercept	Merck	Phase 2	52
ACE-536	Merck	Phase 2	52
luspatercept	Merck	Phase 2	52
Deferasirox	Novartis	Approved	85
Blood sample	Novartis	Pre-clinical	23
deferasirox + placebo	Novartis	Phase 2	52
Zoledronic acid + Placebo	Novartis	Phase 2/3	65
deferasirox	Novartis	Approved	85
deferasirox	Novartis	Phase 3	77
ICL670 + deferoxamine	Novartis	Phase 3	77
Deferasirox	Novartis	Phase 2	52
Deferasirox dispersable tablet (DT) + Deferasirox film coated tablet (FCT)	Novartis	Phase 2	52
Zoledronic Acid	Novartis	Approved	85
Deferasirox	Novartis	Phase 2	52
Deferasirox	Novartis	Approved	85
Deferasirox + Deferoxamine (DFO)	Novartis	Phase 2	52
Deferasirox	Novartis	Phase 1	33
Deferasirox	Novartis	Phase 3	77
Deferasirox	Novartis	Phase 2	52

Other Products from Novartis

LCZ696Approved

zoledronic acidApproved

NateglinideApproved

TenofovirApproved

FTY720Approved